12:00 AM
Mar 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Myocet doxorubicin: Completed Phase III enrollment

Sopherion completed enrollment of 363 patients in an open-label, international Phase III trial evaluating Herceptin trastuzumab and paclitaxel with or without Myocet. Sopherion has...

Read the full 108 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >